Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer | Zendy

Alberto Sobrero | Zendy; Stephen P. Ackland | Zendy; Stephen Clarke | Zendy; R. Pérez-Carrión | Zendy; Silvia Chiara | Zendy; J. Gapski | Zendy; Paul N. Mainwaring | Zendy; Bernd Langer | Zendy; Scott Young | Zendy

Open Access

Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer

Author(s) -

Alberto Sobrero,

Stephen P. Ackland,

Stephen Clarke,

R. Pérez-Carrión,

Silvia Chiara,

J. Gapski,

Paul N. Mainwaring,

Bernd Langer,

Scott Young

Publication year - 2009

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000229787

Subject(s) - bevacizumab , folfiri , medicine , irinotecan , colorectal cancer , fluorouracil , neutropenia , phases of clinical research , bolus (digestion) , adverse effect , oncology , gastroenterology , surgery , chemotherapy , cancer

Bevacizumab (Avastin) significantly improves overall survival (OS) and progression-free survival (PFS) when combined with first-line irinotecan (IFL) plus bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer (CRC). This open-label, phase IV trial evaluated the efficacy and safety of first-line bevacizumab in combination with IFL and infusional 5-FU/LV (FOLFIRI).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research